1993p95-stearns
最值得珍藏的古董音响
最值得珍藏的古董音響所謂的古董音響Vintage Audio,不是看器材的外觀是不是古色古香,而是指約70 年代(含) 之前所生產,而且稱得上是經典(或至少優秀) 的產品。
在這裡,我們放寬標準,把一些80 年代的傑出器材也列入,讓你有更多機種可以參考,選擇。
...論頻寬、解析、動態,古董音響"大多" 不是現代音響的對手,但是,精準又乾淨的聲音一定令人滿意嗎?!事實證明,聽音樂,絕對不只是科學、科技上的追求而已。
古董音響因為...1. 音樂性絕佳,具有大多數現代音響所沒有的獨特感染力。
2. 零件多為真材實料,且多採手工搭棚方式製造,經久耐用。
3. 外觀具獨特風格,對喜好復古的人,有莫名的吸引力。
4. 價格較現代音響產品合理太多(部分炒作過度者除外)。
因而持續受到許多特定音響迷的喜愛。
...不過,想玩古董音響得先有"心理準備"。
撇開外觀的老舊、生鏽、傷痕... 不談,內部零件的老化,甚至毀壞,通常無可避免,勢必要翻新(摩改)。
但大規模的整修,除了得花上不少錢(可能不比買一台老機器便宜),還得擔心原有的老零件難尋,若拿現代零件取代,又可能喪失原有的韻味的尷尬局面(尤其是前級)。
不喜歡"麻煩" 的人,最好三思,要不要踏入古董音響的領域?!...另外,由於本地的氣候潮濕,就算你有幸從國外找得保存狀況良好的器材,也不免很快就鏽蝕斑斑。
建議用防鏽油,定期擦拭保養,才能讓她永保美麗。
...以下為部分最負盛名的"名器"。
但不代表這些器材一定無可挑剔,或無可匹敵。
而且選購時,尚必須考量其二手商品的事實,及零件老化、外觀磨損的狀況,仔細評估,是否值得珍藏?! 價格是否合理?!...物超所值: ★炒作過度: ★外型出眾: ★經典古董喇叭Acoustic Research : AR-3 (1959) ★/ AR-3a (1964) ★Advent : Loudspeaker (Large) (Old) (1969) ★/ Loudspeaker (Large) (New) (1978) ★Altec : A5 (1941) / A7 (1945)Apogee : Scintilla (1980) ★B&W : Matrix 801 (1979) ★/ Matrix 802 (1979) ★Dahlquist : DQ-10 (1974) ★Denon : SC-880 (1988) ★★Diatone : P-610 (1958) ★/ DS-251 (1970) ★/ DS-28B (1974) ★/DS-1000 (1983) ★★/ DS-2000 (1985) ★★/ DS-10000 (1985) ★Dynaco : A-25 (1969) ★EIectro V oice : Patrician 600 (1953) / Patrician 800 (1971)Goodmans : Maxim (1961) ★Jbl : Paragon (D44000) (1957) ★/ L101 (1965) / L100 (1971) ★/4310 (1971) ★/ 4350 (1973) / 4343 (1976) / 4344 (1982)Jensen : G610 + Imperial (1950) ★Harbeth : LS 3/5a (1975) ★★Kenwood : LS-M7 (1989) ★★Kef : LS 3/5a (1975) ★★Klh : Model 6 (1968) ★/ Model 9 (1968) ★Klipsch : Klipschorn (1946) / La Scala (1963) ★/ Belle Klipsch (1971) ★Linn : Isobarik (1976)Onkyo : Monitor 500 (1984) ★★/ D-77XG (1989) ★★Pioneer (Exclusive) : EW-302 (Model 2301) (1982) / S-101 (1987) ★★/ S-701 (1987) ★★/ S-707 (1987) ★★/ S-3000 (1987) ★Quad : ESL-57 (1957) ★/ ESL-63 (1982) ★Rogers : LS 3/5a (1975) ★★/ LS 5/8 (1976) ★/ LS 5/9 (1976) ★Snell : Type A (1978) ★Spendor : BC1 (1972) ★/ LS 3/5a (1975) ★★/ SP1 (1983) ★Spica : TC-50 (1983) ★Amesbury (1974) / Arden (1975) / Cheviot (1975) ★/ Arundel (1982)Technics : SB-10000 (1977) / SB-E100 (1978) / SB-E200 (1978) /SB-MX7 (1987) ★★Victor (Jvc) : SX-3 (1973) ★★/ SX-5 (1973) ★★/ SX-511 (1987) ★★/ SX-500 (1988) ★★/ SX-521 (1988) ★★Yamaha : NS-1000 (1978) ★/ NS-100M (1979) ★經典古董後級- 電晶體Crown : DC 300 (1967) ★Jbl : SE460 (1973) ★Mark Levinson : ML-2 (1977)Quad : 303 (1967) ★經典古董後級- 真空管Acrosound : Stereo 120 (1961) ★Altec : 350A (1959) ★Armstrong : A10 Mk2 (1957)Audiomaster : UL-II (1957) ★/ 11A (1959) ★Bbc : AM8/1 (1957 by Sound Sales) ★/ AM8/4 (1960 by Sound Sales) / AM8/6 (?)Beam Echo (Avantic) : DL7-35 (1958) ★★Conrad-Johnson : MV-75 (1983) ★Dynaco : ST-70 (1959) ★/ ST-35 (1964) ★Eico : HF-14 (1958) / HF-22 (1958) ★/ HF-30 (1958) ★/HF-35 (1958) ★/ HF-50 (1958) / HF-60 (1958)Fisher : 50A (1954) ★/ 50AZ (1955) / 55A (1955) / 80AZ (1955) /30A (1958) / SA-100 (1959) / SA-300 (1960) / SA-1000 (1962) ★/680A (1962) ★Harman Kardon : Citation II (1959) ★/ Citation V (1959) ★Heathkit : W-3M (1954) ★/ W-4M (1958) ★/ W-5M (1958) ★★Leak : TL12 (1948) ★/ TL25 (1948) / TL12.1 (1950) ★/TL25A (1953) / TL12+ (1956) ★/ TL25+ (1956) ★/ TL50+ (1957) ★/ST-20 (1958) / ST-50 (1958) / ST-60 (1961)Lowther : LL15S (1960)Luxman : MB-88 (1966) ★★/ MQ-60 (1969) ★★/ MQ-80 (1974) ★★/ MB-3045 (1976) ★★/ MQ-70 (1978) ★★/ MB-88 Ultimate (1982) ★/ MQ-50 (1983) ★/ MB-300 (1984) ★★/ MQ-360 (1985) ★Marantz : 2 (1956) ★/ 9 (1960) ★★/ 8B (1962) ★★Mcintosh : MC30 (1954) / MC60 (1954) / MC40 (1960) / MC75 (1960) ★/ MC225 (1960) / MC240 (1960) ★/ MC275 (1962) ★Michaelson & Austin : TV A-1 (1970) ★Pilot : AA-901 (1952) / SA-232 (1958) ★/ SA-260 (1958) ★/SA-264 (1961) ★Pye : PF91 (1954) / HF25 (1958) / HFS20 (Mozart) (1959)Quad : II (1954) ★Radford : STA12 (1960) / MA15 (1961) / STA15 (1962) / MA25 (1962) ★/ STA25 (1965)Radio Craftsmen : C500 (1953)Rca : MI-9377 (1954) / MI-12191 (SP-20) (1954) ★/ LMI-32216 (1957) ★★Rogers : Cadet II (1963) / Cadet III (1964)Scott : 208 (1961) ★Sound Sales : Model 12/14 (1946) / A-Z Junior (?)Stromberg-Carlson : AP-55 (1955) ★/ AP-428 (1957) ★Western Electric : 86B (1934) ★/ 91A (1936) ★/ 124 (1939) ★/131A (1940) ★/ 142A (1942) ★/ KS-16608 (?) ★經典古董前級- 電晶體Audio Research : SP-5 (1977) ★Jbl : SG520 (1973) ★Marantz : 7T (1967) ★Mark Levinson: LNP-2 (1975) ★/ LNP-2L (1977) ★Quad : 33 (1967) ★經典古董前級- 真空管P.S. 約1956 年前生產的古董前級,只有mono 輸出,所以需要兩台,請注意! Audio Research : SP-3 (1972) ★/ SP-6 (1978) ★/ SP-10 (1982) ★/SP-11 (1985) ★/ SP-9 (1987) ★Beam Echo (Avantic) : SP-21 (1959) ★Conrad Johnson : PV-2a (1981) ★/ Premier 3 (1983) ★Counterpoint : SA-11 (1984) / SA-5000 (1990)Dynaco : PAM-1 (1957)Eico : HF-65 (1956) / HF-85 (1958) / ST-84 (1960) ★Electro V oice : PRC-1 (1955)Fisher : 50-C (1953) ★/ 80-C (1956) / 400-C (1959) ★/400-CX (1961) ★/ 400-CX II (1962) ★Grommes : 211 (1956) / 207 (1957) / 209 (1960)Heathkit : WA-P2 (1954) ★★Lafayette : KT-300 (1957) ★/ KT-600 (1958) ★Leak : Varislope (1952) ★/ Varislope II (1954) ★/ Varislope Ⅲ(1956) ★/ Varislope Stereo (1962) ★/ Varislope 2 Stereo (1965) ★Luxman : CL-35 (1970) ★Marantz : 7C (1959) ★★Mcintosh : C20 (1959) ★/ C11 (1961) ★/ C22 (1962) ★★Pilot : PA-911 (1952) / PA-913 (1955) / SP-210 (1958) ★/SP-215 (1959) / SP-216 (1960)Pye : PF91A (1954) / HF25A (1958) / HFS20 (Mozart) (1959)Quad : 22 (1957) ★Radio Craftsmen : C300 (1953) / C350 (1954)Rca : MI-12150 (1953) / LMI-32215 (1957) ★Scott : 121-A (1953) / 121-C (1956) / 130 (1958) / 122 (1960) ★/LC-21 (1961)Siemens : 6SELA 2154 (1959)Sound Sales : A-Z Junior (?)經典古董綜合擴大機- 電晶體Accuphase : E-303 (1978) ★/ E-302 (1984) ★★Denon : PMA-970 (1980) ★★/ PMA-790 (1982) ★Hitachi (Lo-D) : HA-500F (1975) ★★/ HA-1100 (1975) ★★Jbl : SA600 (1966) ★Kenwood (Trio) : KA-7300 (1975) ★/ KA-9300 (1976) ★/ KA-9900 (1978) ★Kyocera : A-710 (1985) ★★Luxman : L-309 (1973) ★★/ L-100 (1975) ★★/ L-58A (1979) ★★Marantz : 1060 (1971) ★/ 1122DC (1977) ★McIntosh : MA5100 (1966) ★★ / MA6100 (1972) ★★/ MA6200 (1978) ★Nad : 3020 (1978) ★Pioneer (Exclusive) : SA-910 (1973) ★/ SA-9900 (1974) ★/ A-900 (1979) ★Sansui : AU-777 (1967) ★/ AU-9500 (1972) ★/ AU-7700 (1975) ★★/AU-9900 (1975) ★Sony : TA-1120F (1972) ★/ TA-F333ESX (1986) ★Victor : JA-S75 (1976) ★★/ A-X9 (1979) ★★/ A-X77 (1982) ★Yamaha : CA-1000 (1973) ★/ A-9 (1979) ★/ A-2000 (1983) ★經典古董綜合擴大機- 真空管Bell : 2199 (1956) / 3DT (1957) ★Dynaco : SCA-35 (1964) ★Eico : HF-81 (1959) ★/ AF-4 (1964) ★Electro V oice : A-20 (1956)Fisher : X-100 (1959) ★/ X-101 (1961) ★/ X-202 (1962) ★/KX-200 (1962) ★/ X-1000 (1962) ★Heathkit : AA-191 (1954)Luxman : SQ-38D (1964) ★/ SQ-38FD (1970) ★/ SQ-38FD II (1974) ★/L-38 (1978) ★/ LX-38U (1981) ★Mcintosh : MA230 (1963) ★Rogers : Cadet III (1964) ★Sansui : AU-111 (1965) ★★Scott : 299 (1960) ★/ 299C (1961) ★經典古董收音擴大機(Receiver)Fisher : 400 (1964) ★★/ 500-C (1964) ★★Kenwood (Trio) : KR-5600 (1977) ★/ KR-4070 (1978) ★Marantz : 2285 (1977) ★/ 2385 (1977) ★Mcintosh : MAC 1500 (1965) ★★/ MAC 1700 (1967) ★★/ MAC 1900 (1974) ★Pilot : 654 (1962) ★Pioneer (Exclusive) : C-2000 (1969) ★★/ SX-800A (1969) ★★/SX-434 (1973) ★/ SX-1250 (1976) ★/ SX-1980 (1978) ★Sansui : 500 (1964) ★★/ 500A (1964) ★★/ 1000A (1964) ★★/1000X (1967) ★★/ SAX-500 (1967) ★★/ QRX-6500 (1973) ★/9090 (1976) ★經典古董收音機(Tuner)Kenwood (Trio): KT-815 (1980) ★/ KT-917 (1980) ★/ L-01T (1979) ★/L-02T (1982) ★Marantz : 10B (1964) ★★Mcintosh : MR65 (1960) ★★/ MR67 (1963) ★★/ MR71 (1965) ★★/ MR78 (1972) ★/ MR80 (1973) ★Pioneer (Exclusive) : TX-9500 (1977) ★/ TX-9800 (1979) ★Sansui : TU-717 (1977) ★/ TU-919 (1979) ★經典古董LP 轉盤- 惰輪Dual : 1019 (1970) ★/ 1219 (1971) ★Emt : 927 (1951) ★/ 930 (1956) ★Garrard : 301 (1954) ★★/ 401 (1965) ★Lenco : L75 (1967) ★Rek-O-Kut : B-12H (1954) ★Thorens : TD 124 (1956) ★★經典古董LP 轉盤- 皮帶Acoustic Research : AR Turntable (1961) ★/ AR XA (1963) ★Ariston : RD11 (1971) ★/ RD80 (1983) ★/ RD40 (1984) ★Connoisseur : BD2/A (1977) ★Empire : 208 (1960) ★/ 598 (1965) ★Linn : Sondek LP12 (1972) ★★/ Axis (1987) ★★Luxman : PD 300 (1982) ★Micro Seiki : BL-51 (1980) ★★/ BL-71 (1980) ★★/ BL-91 (1980) ★★/ SX-777 (1981) ★/ BL-77 (1982) ★★/ RX-2000 (1982) ★Rega : Planar 3 (1977) ★Thorens : TD 150 (1966) ★/ TD 125 (1969) ★/ TD 160 (1972) ★/經典古董LP 轉盤- 直驅Denon : DP-80 (1978) ★★/ DP-60L (1980) ★★/ DP-75M (1981) ★★/DP-100M (1982) ★Emt : 938 (1982) ★★Kenwood (Trio) : KD-500 (1976) ★★/ L-07D (1979) ★/ KP-700 (1981) ★★/ KP-1100 (1985) ★★Luxman : PD 441 (1978) ★★/ PD 444 (1978) ★★Micro Seiki : DD-100 (1976) ★★Pioneer (Exclusive) : P10 (1979) ★/ PL-50 (1980) ★★/ PL-70 (1981) ★★/ P3a (1983) ★Sansui : SR-838 (1977) ★★/ SR-929 (1977) ★★Sony : PS-X9 (1977) ★/ PS-X800 (1981) ★Technics : SP-10 (1970) ★★/ SL-1200 (1972) ★/ SP-15 (1979) ★Thorens : TD 524 (1982) ★★Toshiba (Aurex) : SR-P90 (1982) ★★Victor : QL-7R (1977) ★★/ QL-A95 (1982) ★★/ QL-A70 (1983) ★★Yamaha : GT-2000 (1982) ★★/ GT-1000 (1983) ★★經典古董唱臂Audiocraft : AC-3000、AC-4000 (1980) ★/ AC-3300、AC-4400 (1984) ★★Empire : 980 (1963) ★/ 990 (1965) ★Fidelity Research : FR-64、FR-66 (1978) ★★Grace : G-707 (1979) ★Linn : Ittok LV II (1979) ★/ Basik Plus (LVX+) (1987) ★Micro Seiki : MA-505 (1980) ★/ MAX-237、MAX-282 (1980) ★★Ortofon : RMG-212、RMG-309 (1959) ★★/ RS-212、RS-309 (1959) ★Rega : RB300 (1983) ★Sme : 3009、3012 (1959)Stax : UA-7、UA-70 (1970) ★★/ UA-9、UA-90 (1979) ★經典古董唱頭從缺(選購時盡量以新品為主)經典古董CD 唱盤從缺(選購時盡量以新品為主)經典古董線材Audio Research : Litz (?) ★Cello : Strings (?) ★Kimber Kable : 4PR (1979) ★/ 4TC (1985) ★Western Electric : 各種線材(1930、40) ★...古董音響中的四大天王P.S.以下排名僅供"趣味性" 或"選購時" 之參考,主要依據目前市場上"大致的評價",但不代表其品質,或表現,無可匹敵,或無可挑剔。
第三章动物细胞制药part2讲课教案
动物细胞培养方法和操作方式
一、动物细胞大规模培养方法 依细胞种类: 原代培养 传代培养 依培养基: 液体培养基 固体培养基
依培养器和方式:
静止培养、旋转培养 搅拌培养、为载体培养 中空纤维培养、 固定床或流化床培养
Байду номын сангаас
从生产实际分为:
悬浮培养 贴壁培养 贴壁-悬浮培养
培养技术
动物细胞大规模培养与实验室培养相比,培养条件 更严格,控制难度更大,其培养方法可概括为:
支持细胞贴附生长。 ⑵ 钛碟装置多层圆柱状不锈钢(带有观察条件)罐内或
玻璃瓶内装入钛碟圆盘支持细胞贴服生长。可改变 位置和旋转。
培养技术
1. 细胞悬浮培养法
➢ 动物细胞在培养液中呈悬浮状态生长繁殖的培养方 法谓之悬浮培养法。其培养方式有
批量法 半连续法 连续法 ➢ 适用于培养确立细胞株、杂交瘤细胞、肿瘤细胞、 血液细胞及淋巴组织细胞,用于大量生产疫苗、 α-干扰素、白介素等药品。 ➢ 此法不适于包括二倍体细胞在内的正常组织细胞的培 养。
培养技术 细胞悬浮培养法的优点
➢ 可连续收集部分细胞进行移植继代培养,传代时无需 消化分散,免遭酶类、EDTA及机械损害。
➢ 细胞收率高,并可连续测定细胞浓度,还有可能实现 大规模直接克隆培养。
培养技术
细胞悬浮培养法的优点
➢ 培养过程中,为确保细胞呈单颗粒均匀悬浮状态, 需采用搅拌或气升式反应器,以较低搅拌速度及 一定速度通入含5%的CO2无菌空气,保持细胞悬浮态 并维持培养液溶解氧。
Vero细胞和狂犬病毒的培养工艺
动物细胞培养存在的问题
细胞密度低,细胞生产率低,产物浓度也很低。 细胞群体在大规模、长时间培养过程中分泌产物能力
五种型号进口自体血液回收机性能比较
五种型号进口自体血液回收机性能比较
HCT探头
德国-费森尤斯CATS
产品外型尺寸:42 cm x 51 cm x 70 cm 美国唯血Haemonetics CELL SAVER 5/5+
产品外型尺寸:41 cm × 37 cm×94 cm
美国-美敦力Autolog
外型尺寸:33 × 22×75 cm 意大利-索林BRAT/( BRAT2)
外型尺寸:52cm × 53 cm×89 cm 意大利-索林Electa
外型尺寸:27× 60× 58.5 cm 意大利-索林XTRA
外型尺寸:37.5× 50× 66 cm
3000P
外型尺寸:49X36X27.6CM
纵向型式外型尺寸横向型式外型尺寸
关于小型分体式血液回收机需确定的问题1、产品采用横向型式还是纵向型式?
从现有国外产品看这两种型式的产品都存在。
2、液晶屏采用多大比较合适?
国外产品有为8.4吋(172X130mm)。
3、液晶屏摆放的位置、角度?
将影响到操作方便程度、视觉效果。
Eaton Power Xpert 9395P 600kVA 550kW UPS技术规范说明书
The technical specification is subject to change without notice.
Author: Joel Kärkkäinen
Page 3 of 5
Updated: 31.10.2017
Document: Pow er Xpert 9395P-600 technical spec ification_Rev007
Eaton Power Xpert 9395P 600kVA/550kW UPS Technical Specification
Manufacturer’s declaration in accordance with IEC 62040-3
IEC 62040-3
Subclause
MODEL RATING (0,9 p.f.)
25% load
Efficiency in ESS,
rated linear load
6,3kW
No load
4,3 kW
100% load
99,3 %
75% load
99,3 %
50% load
25% load
99,2 %
99,0 %
ELECTRICAL CHARACTERISTICS
INPUT
5.2.1.a
Up to 7 units w ith centralized bypass
5.1.1
UPS topology
Double conversion, IGBT converters
5.3.4
UPS performance classification
VFI-SS-111
MECHANICAL
安捷伦产品目录
15
Real-Time PCR
16
Mx3000P QPCR System
17
Brilliant III Ultra-Fast SYBR Green QPCR and QRT-PCR Reagents
18
Brilliant III Ultra-Fast QPCR and QRT-PCR Reagents
Agilent / STRATAGENE
Agilent website: /genomics
Welgene | Agilent Stratagene
威健股份有限公司 | Stratagene 總代理
Table of Content
Table of Contents
/ XL1-Red Competent Cells SoloPack Gold Supercompetent Cells
/ TK Competent Cells Specialty Cells
/ Classic Cells / Fine Chemicals For Competent Cells
適用於 UNG 去汙染或 bisulphite
sequencing
適用於 TA Cloning
最高敏感性
取代傳統 Taq 的好選擇
-
2
威健股份有限公司 | Stratagene 總代理
PCR Enzyme & Instrument
Agilent SureCycler 8800
市場上領先的 cycling 速度和 sample 體積 10 ~ 100 μL 簡易快速可以選擇 96 well 和 384 well 操作盤 優秀的溫控設備讓各個 well 都能保持溫度的穩定 七吋的高解析度觸控螢幕讓操作上更為簡便 可以透過網路遠端操控儀器及監控儀器 Agilent 專業的技術支援可以幫助您應對各種 PCR 的問題
含有胃促胰酶抑制剂作为有效成分的预防或治疗纤维变性的药物[发明专利]
专利名称:含有胃促胰酶抑制剂作为有效成分的预防或治疗纤维变性的药物
专利类型:发明专利
发明人:深见治一,奥西秀树,柿添荣一
申请号:CN01800794.5
申请日:20010222
公开号:CN1366461A
公开日:
20020828
专利内容由知识产权出版社提供
摘要:一种抑制皮肤或其它各种器官的纤维发生的发展同时预防多种并发症的发展的预防性或治疗性药物,并且由于其无副作用而是如此的安全以致于可提高患者的每日生活质量。
具体地,含有胃促胰酶抑制剂作为活性成分的纤维变性的预防性或治疗性药物,其中的胃促胰酶抑制剂是通式(I)的喹唑啉衍生物或其药用盐。
申请人:三得利株式会社
地址:日本大阪
国籍:JP
代理机构:中国国际贸易促进委员会专利商标事务所
代理人:程金山
更多信息请下载全文后查看。
非凡的酶
商品名称:非凡的酶
产品目录号:01706
主要成分:营养吸收混合物200毫克
蛋白酶SP(芽孢杆菌,米曲霉)97,000 HUT
蛋白酶S(蜂蜜曲霉)10,500PC
酸性蛋白酶(黑曲霉)10 SAPU
脂肪酶(皱落假丝酵母,米根霉,黑
4,000 FIP
曲霉)
纤维素酶(长枝木霉)2,400 CU
胰蛋白酶(猪)20,000 USP
胰凝乳蛋白酶(猪)3,336 USP
木聚糖酶(长枝木霉)600XU
肌醇六磷酸酶(黑曲霉)20FTU
β-葡聚糖酶(长枝木霉)30 BGU
半纤维素酶(黑曲霉)4,000 HCU
果胶酶(黑曲霉)50endo-PGU
其他成分:木薯麦芽糊精、蔬菜纤维素(胶囊)、玉米麦芽糊精、中链甘油三酸酯(椰子)、牛奶、大豆、坚果(椰子)、小麦。
规格型号:60颗
用法用量:每天两次,每次一颗胶囊,正餐前服用,或听从医嘱。
注意事项:本品不能代替药品
贮藏:保持阴凉密封
有效期:24个月
生产企业:High Quality Vitamins Supplement Inc.(高品质维生素膳食补充剂公司)
国内总代理销售:健客保健品商城
产品介绍:调节血糖、帮助消化促进吸收
不适宜人群:无。
h1975细胞突变类型
h1975细胞突变类型
H1975细胞是一种肺癌细胞系,常用于研究非小细胞肺癌(non-small cell lung cancer, NSCLC)的发病机制和药物敏感性。
H1975细胞具有以下两种突变类型:
1. EGFR突变:H1975细胞最显著的突变是在表皮生长因子受体(EGFR)基因上出现两个常见突变,即T790M和L858R。
L858R突变导致EGFR激酶活性增强,促进细胞生长和存活。
而T790M突变则是耐药突变,使得EGFR抑制剂的治疗效果降低。
2. TP53突变:H1975细胞还携带肿瘤蛋白53(TP53)基因上的突变。
TP53是一个重要的肿瘤抑制基因,负责维持基因组稳定性和调节细胞周期。
TP53突变可能导致其功能丧失,从而增加细胞的恶性转化和耐药性。
这些突变使得H1975细胞表现出高度侵袭性和耐药性,对于研究肺癌的发展机制和评估新型治疗策略具有重要意义。
珍品国药劲仕 成就品味男人
珍品国药劲仕成就品味男人1998年,在美国加利福尼亚州多地发生了大黄蜂攻击居民事件,当地政府用农药催毁大黄蜂老巢后,仅过半个月,在居民周围又出现了成千上万的黄蜂群,恐怖气氛迅速蔓延。
由于事态严重,加州政府迅速求助国家科学院的生物学专家威尔逊院士,威尔逊院士在对活体大黄蜂研究后甚为吃惊,这些大黄蜂繁殖力惊人,他们以每秒一只的速度繁殖,这些漏网的大黄蜂半个月时间又繁殖出了数以万计幼蜂。
这种"恐怖杀手"繁殖能力怎么会有这么强大?难道他们身上蕴藏着人类未知的能量?威尔逊院士考虑把大黄蜂赶走的同时,其超强的繁殖能力更让他感兴趣。
两个月后,大黄蜂在市区消失了,威尔逊院士着手研究其超强繁殖能力,他从大黄蜂的雄蜂蛹中萃取出一种HDV 的活性因子,就是这种活性因子提供的营养蛋白让蜂王繁殖数亿只幼蜂。
如果把HDV活性因子用于提高男性功能将会怎样?1200名志愿者用后仅4天,这些志愿者性欲提升,性事持久,快感增加显著,服用三个月后,原本羸弱的身体变的非常强壮,体毛粗黑油亮,晚上睡的香,白天精神爽,性欲提升近3倍,同时,普遍反映器官更为粗壮,增长6cm之多,睾丸增大、重量增加,精液量增多,射精有力。
两年后,这些志愿者身体依然健壮无比,并且无任何反弹现象。
2000年,威尔逊院士在《自然》杂志发表了题为《大黄蜂与男性功能提升》的论文。
第一次科学的论证了雄蜂蛹提取物HDV能够促进阴茎发育全面提升男性性能力。
巨资买断,独家拥有!2001年,中国医药考察团赴美进行学术交流,意外看到了有关雄蜂蛹HDV的论文报告,银诺克集团第一时间联系到威尔逊院士,巨资买断雄蜂蛹HDV提取专利技术,并依靠长白山得天独厚的自然条件建立了万亩大黄蜂养殖基地,每年提供数万吨雄蜂蛹以供提取HDV因子。
2002年,银诺克集团生产出了我国第一个以雄蜂蛹,蜂王浆、兔睾丸、人参叶皂苷、沙苑子、枸杞子为主要配方的“劲仕牌参雄温阳胶囊”。
并被国家药监局批准为国药准字,列为一类新药,劲仕胶囊的诞生,第一次让男人品味上了绿色、安全、功效全面的男性产品。
美国阿格迪agdia公司转基因检测产品
STX74000/0050
50条
2450
阳性质控物
LPC73000
220
8Байду номын сангаас
Bt-Cry1F, ELISA DAS ELISA
内毒素蛋白检测试剂盒
过氧化物酶标记物
PSP10301/0096
96反应孔
2660
PSP10301/0288
288反应孔
4600
PSP10301/0480
480反应孔
6.Bt-Cry1F and Bt-Cry34Ab1货号:STX10900/0050规格:50条报价:2240元
7.Bt-Cry2A货号:STX05801/0050规格:50条报价:1540元
8.Bt-Cry34Ab1货号:STX04500/0050规格:50条报价:1540元
9.Bt-Cry3Bb1货号:STX06100/0050规格:50条报价:1540元
多克隆抗体/多克隆抗体,碱性磷酸酶标记物
PSA05900/0096
96反应孔
2660
PSA05900/0288
288反应孔
4600
PSA05900/0480
480反应孔
7210
PSA05900/4800
4800反应孔
38920
Bt-Cry3AImmunoStrip检测试纸条,必须与SEB4样品提取缓冲液结合使用,请另外购买SEB4缓冲液。
10.mBt-Cry3A货号:STX06700/0050规格:50条报价:1540元
11.neomycin phosphotransferase II货号:STX73000/0050规格:50条报价:2450元
工业上有用的微生物[发明专利]
专利名称:工业上有用的微生物专利类型:发明专利
发明人:沟口宽,原清敬,森英郎申请号:CN200580047094.7申请日:20051125
公开号:CN101115832A
公开日:
20080130
专利内容由知识产权出版社提供
摘要:根据本发明,能够提供具有比野生型大肠杆菌的染色体DNA短470kbp以上的染色体DNA 的大肠杆菌突变体,该大肠杆菌突变体在经过一定时间的培养后,菌体数比野生型株多,据此通过将该突变体在培养基中进行培养,使之在培养物中生成、蓄积有用物质,能够很有效率地制备有用物质,例如:蛋白质、肽、氨基酸、核酸、维生素、糖、有机酸以及脂类等。
申请人:协和发酵工业株式会社
地址:日本东京
国籍:JP
代理机构:中国国际贸易促进委员会专利商标事务所
代理人:罗菊华
更多信息请下载全文后查看。
单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性
专利名称:单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途专利类型:发明专利
发明人:C.希尔特-迪特里希,P.桑德纳,J-P.施塔施,A.克诺尔,G.冯德根费尔德,M.哈恩,M.福尔曼
申请号:CN201180036565.X
申请日:20110524
公开号:CN103038232A
公开日:
20130410
专利内容由知识产权出版社提供
摘要:单独的或与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于预防和治疗纤维化疾病(诸如系统性硬化症、硬皮病和伴随的内脏器官纤维化)的用途。
申请人:拜耳知识产权有限责任公司
地址:德国蒙海姆
国籍:DE
代理机构:中国专利代理(香港)有限公司
更多信息请下载全文后查看。
用于抗生素的稳定组合物以及应用方法[发明专利]
专利名称:用于抗生素的稳定组合物以及应用方法专利类型:发明专利
发明人:高深,丹尼尔·A·莫罗斯,萨蒂什·阿索特拉申请号:CN200780035206.6
申请日:20070926
公开号:CN101516334A
公开日:
20090826
专利内容由知识产权出版社提供
摘要:本发明涉及改善的液体抗生素剂型。
在某些实施方式中,本发明涉及一种包括在包含甘油三酯的液体中的抗生素的组合物,其中上述组合物具有少于约5%(w/v)的水。
申请人:塔罗制药北美有限公司
地址:英属开曼群岛
国籍:KY
代理机构:北京康信知识产权代理有限责任公司
更多信息请下载全文后查看。
葡萄球菌属细菌的营养缺陷型菌株[发明专利]
专利名称:葡萄球菌属细菌的营养缺陷型菌株专利类型:发明专利
发明人:T·M·惠特菲尔,邓明德,D·R·杜德兹
申请号:CN201980017381.5
申请日:20190104
公开号:CN111788299A
公开日:
20201016
专利内容由知识产权出版社提供
摘要:本公开内容提供了依赖于D‑丙氨酸用于生长的重组葡萄球菌属细菌(例如表皮葡萄球菌)。
在一个方面,本公开内容的特点在于重组葡萄球菌属细菌,其包含两个失活的丙氨酸消旋酶基因(Δalr1Δalr2);以及失活的D‑丙氨酸转氨酶(dat)基因。
在另一个方面,本公开内容的特点在于制备重组葡萄球菌属细菌的方法。
申请人:阿兹特拉公司
地址:美国康涅狄格州
国籍:US
代理机构:中国专利代理(香港)有限公司
更多信息请下载全文后查看。
高密度脂蛋白中的胆固醇的测定方法以及试剂[发明专利]
专利名称:高密度脂蛋白中的胆固醇的测定方法以及试剂专利类型:发明专利
发明人:片山有基,藤中真由美
申请号:CN200380100779.4
申请日:20031016
公开号:CN1694965A
公开日:
20051109
专利内容由知识产权出版社提供
摘要:试样中的高密度脂蛋白中的胆固醇的测定方法以及试剂,其特征在于:在含有i)非离子性表面活性剂、聚阴离子以及白蛋白或者ii)聚环氧乙烷烷基胺或者聚环氧乙烷烯基胺以及环氧乙烷多环苯基醚硫酸酯或阴离子胆汁酸衍生物的水性介质中,使试样和i)胆固醇酯水解酶以及胆固醇氧化酶、或者ii)胆固醇酯水解酶、氧化型辅酶以及胆固醇脱氢酶反应,测定生成的过氧化氢或者还原型辅酶。
申请人:协和梅迪克斯株式会社
地址:日本东京
国籍:JP
代理机构:中国国际贸易促进委员会专利商标事务所
代理人:陈昕
更多信息请下载全文后查看。
美国医学遗传学会-临床遗传实验室标准和指南
AMERICAN COLLEGE OF MEDICAL GENETICSStandards and Guidelines for Clinical Genetics Laboratories2006 Edition.E: CLINICAL CYTOGENETICSE1Cell CultureSee D1.E2RecordsE2.1Retention of Case MaterialsIn addition to the general guideline (C3.6) for duration of retention of casematerials, the following are specific to cytogenetics.E2.1.1Slides used for diagnostic tests have a limited lifespan. If stained with a "permanent" banding method (G-, C- or R-banded, NOR), slides should be kept atleast 3 years or in compliance with state regulations. Retention time of thosewith fluorochrome stained chromosomes is at the discretion of the laboratorydirector.E2.1.2Each laboratory should establish a policy to assure that any residual original patient specimens, cell cultures or pellets are retained until adequate metaphasepreparations are available to complete the requested analysis.E2.1.3Processed patient specimens should be retained until the final report has been signed. Long-term retention time of those with abnormal results is at thediscretion of the laboratory director.E3Procedural GuidelinesE3.1General Analytical StandardsE3.1.1TerminologyChromosome counts are defined as the number of centric chromosomes per metaphasecell. During the establishment of the modal number for a study, all aneuploidmetaphase cells should be characterized for specific gain/loss.Analyzed cells are defined as banded metaphase cells in which the individualchromosomes are evaluated in their entirety, either at the microscope or fromintact digitized images or photographic prints of intact cells.Karyotyped cells are defined as the cutout and paired chromosomes from photograph(s) or computer-generated image(s) from a single cell following the format in AnInternational System for Human Cytogenetic Nomenclature 1995 (ISCN 1995).Scored cells refers to cells evaluated for the presence or absence of a specificcytogenetic feature, usually indicated by either a particular clinical history orby the finding of one or two abnormal cells during the course of a study. Numbersof cells to be scored in most situations are left to the discretion of thelaboratory director, unless otherwise specified in the guidelines.A colony is defined as a discrete focus or clone of cells that is harvested andstained while attached to the cell culture growth substrate.An abnormal clone is present if at least two cells contain the same extrachromosome(s) or structural chromosome abnormality or if at least three cellshave lost the same chromosome.E3.1.2Slide number and microscope stage coordinates should be recorded for all metaphases analyzed or counted. If additional cells are evaluated in questions ofmosaicism, slide number should be recorded for all cells that are scored andslide coordinates should be recorded for all abnormal metaphases or suspectedabnormal metaphases.E3.1.3All laboratories must be able to perform studies using G- and/or R-banding, in addition to special stains and/or FISH, to characterize polymorphisms, whenindicated and at the discretion of the laboratory director.E3.1.4ISCN 1995 must be used to describe all karyotypes.E3.1.5 A number of different objective methods have been described for the calculation of band stage of resolution [1,2,3]. One or more objective and reproduciblemethod(s) must be used to assess banding level of resolution and must be formallydescribed in laboratory standard operating procedures/protocol manual. Specificstandards for resolution should be appropriate to the case and type of tissuestudied. The 550-band stage should be the goal of all constitutional studies torule out a structural abnormality, particularly in cases of mental retardation,birth defects, dysmorphology, or couples with recurrent pregnancy loss.E3.1.6Minimum standards established for the numbers of cells to count and/or analyze and karyotype during the "routine" component of a cytogenetic study are describedin specific subsections appropriate to a specific tissue type, culture methodand/or reason for referral. The numbers of cells to study in individualsituations is dependent on the specific abnormality observed, the tissue beingexamined, whether the analysis involves prenatal diagnosis, etc. Generalrecommendations are noted in the following subsections.E3.1.6.1Each laboratory should establish guidelines for procedures (e.g., numbers of cells to score) to follow for each general type of abnormality (hypodiploidy,hyperdiploidy and structural abnormality) with the recognition that uniformityamong laboratories is not required.E3.1.6.2Guidelines should be based on current knowledge of the potential clinicalsignificance of particular chromosome abnormalities and nonmodal cells.E3.1.6.3Fewer cells than indicated under analytical standards may be studied in circumstances in which screening for a specific abnormality is the indication forthe study (e.g., checking for a known familial abnormality) or when anabnormality is detected but no more cells are available (see following section).E3.1.7Analyses should be performed and/or evaluated by at least two qualified individuals.E3.2Abbreviated, Focused or Limited Chromosome StudiesE3.2.1General ConsiderationsE3.2.1.1It is acknowledged that there are specific clinical circumstances for which an abbreviated or limited cytogenetic study may be appropriate. For example, in thetissue confirmation of an abnormal prenatal chromosome result or in peripheralblood chromosome studies on extended family members to exclude an identifiedchromosome rearrangement, limited analyses may be suitable.E3.2.2Analytical StandardsThe laboratory should have established written criteria for which focused orabbreviated studies are permissible. Criteria should specifically address therationale for such studies, the clinical reason for referral, the tissue type,and the minimum number of cells counted, analyzed and karyotyped under suchcircumstances.E3.3Maternal Cell Contamination (MCC)E3.3.1Maternal cell contamination of amniotic fluid and chorionic villi cell cultures is well documented and therefore represents a potential source of error inprenatal diagnosis. Adequate measures to minimize the inclusion of maternal cellsin prenatal samples should be part of the laboratory quality assurance program.E3.3.1.1Amniotic FluidThe overall frequency of MCC is approximately 0.5% of genetic amniocenteses [4].Factors that increase the chance of MCC include the gauge of needle used for theamniocentesis procedure [5], the length of time in culture and the presence ofblood in the sample.It has also been documented that cultures initiated from the first 1-2 ml ofamniotic fluid drawn at amniocentesis are at an increased risk for maternal cellcontamination [5]. It is recommended that the first few milliliters of fluid belabeled appropriately and kept separate from the remaining sample to minimizeinclusion of maternal cells. The initial aliquot should be used for cytogeneticanalysis only if absolutely necessary.E3.3.1.2Chorionic Villi Sampling (CVS)The risk for MCC in CVS is significantly higher than for amniocentesis samples(1-2%) [6]. A CVS specimen must be viewed under a dissecting microscope to allowfor the gross identification and cleaning of villi from maternal decidua, bloodvessels, membrane and other materials. It is recommendred that sterileinstruments (e.g., probes, scissors, tweezers) be used to tease apart the sampleto isolate the fetal chorionic villi from maternal decidua. It may be helpful tohave two laboratory technologists clean or check the dissected tissue prior toinitiating cultures.E3.3.1.3Products of ConceptionDue to the manner in which abortus tissue and placenta samples are obtained andhandled, there is a substantial risk of MCC, particularly in early fetal lossspecimens. It is recommended that appropriate measures be taken to specificallyidentify fetal tissues and to dissect and culture only these tissues, asdescribed above for prenatal CVS. Consultation with the referring physician maybe warranted to determine the origin of the sample and/or the appropriateness ofchromosome studies, particularly in cases for which the dissection of tissueappears to yield only maternal decidua.E3.3.2Analysis of Cultures with Known or Suspected MCCCultures with known or suspected MCC based on the condition of the specimen atreceipt, or apparent maternal cells morphologically in culture, require variationin the normal analysis procedure. If XX cells are found in an otherwise XY study,the most likely explanation is MCC. Since the true fetal cells are probablyrepresented by the XY complement, the full analysis and cell counts should beperformed on these cells whenever possible. Counting and analyzing several cellswith an XX constitution is recommended for documentation purposes. For prenataltesting, further studies may be warranted to exclude chimerism. Ultrasoundexamination to check the gender of the fetus, second amniocentesis orconfirmatory amniocentesis after CVS and/or polymorphism studies (cytogenetic ormolecular) between a maternal sample and the fetal sample may be required in theinvestigation.If cell cultures that are initiated in the cytogenetics laboratory are to be usedfor molecular or biochemical testing, any serious concerns about MCC in thosecultures must be conveyed to the molecular or biochemical testing laboratory. Inaddition, if direct prenatal samples are sent out for testing, it is recommendedthat back-up cultures be grown and maintained until the molecular or biochemicaltesting is complete and reported.E3.3.3MCC Reporting and Quality AssuranceReporting of MCC is case-dependent and is at the discretion of the laboratorydirector. Consultation with the referring physician is recommended, whenappropriate. Any significant observation of MCC in a prenatal diagnosis sampleshould be interpreted in consultation with the physician who performed theprocedure. For samples with a significant risk for MCC that produce a normalfemale karyotype, a disclaimer should be added to the report suggesting thatanalysis of maternal cells due to MCC cannot be excluded.Any time that MCC is suspected or confirmed, the laboratory director must ensurethat an attempt to determine the cause is documented as part of the laboratory'squality assurance program. Additionally, it is recommended that the ratio ofXX:XY cases be monitored as a quality control check for CVS and POC cases.E4Prenatal DiagnosisE4.1Amniotic Fluid, Chorionic Villi and Percutaneous Umbilical Blood Sampling (PUBS)E4.1.1General StandardsE4.1.1.l At least two independent cell cultures must be initiated and grown in separate incubators.E4.1.1.2With the exception of PUBS, there must be a plan for maintaining back-up cell culture(s) pending the need for additional studies.E4.1.1.3If studies of parental chromosomes are necessary to help identify a fetal chromosome abnormality or heteromorphism, the same laboratory should performthese, if possible and reasonable under the specific constraints of the clinicalindications.E4.1.1.4The number of test failures (defined as failure to obtain final results from a submitted specimen) should not exceed 1 per 100 consecutive samples (1%).E4.1.1.5Efforts must be made to determine the cause of all test failures. These records and records of corrective actions taken must be available for external review andkept for at least 1 year.E4.1.1.6With the exception of PUBS, at least 90% of final results must be completed and reported (verbal or written) within 14 calendar days from receipt of specimen,unless additional studies are necessary.E4.1.1.7Laboratories failing to meet these standards should send samples to another laboratory until the problems are resolved.E4.1.1.8Abnormal diagnostic results should be confirmed by follow-up cytogenetic studies, to the extent possible.E4.1.2Amniotic Fluid: Processing StandardsE4.1.2.1If little or no cell pellet is apparent in the sample, the laboratory should consider the use of a method (e.g., assays for pH, protein, glucose, etc.) thatwill help to distinguish amniotic from other fluids.E4.1.2.2Notification of inadequate cell culture growth should be made within 14 days of the amniocentesis procedure.E4.1.2.3 A laboratory planning to establish amniotic fluid cytogenetic testing must arrange to split and successfully analyze at least 50 consecutive specimens witha laboratory performing such studies by established standards.E4.1.3Amniotic Fluid: Analytical Standards (see also E3.1.6)E4.1.3.1Flask Techniquea.Count: a minimum of 20 cells, distributed as equally as possible between atleast 2 independently established cultures. Document anynumerical/structural aberrations observed.b.Analyze: 5 cells, distributed between at least 2 independently establishedcultures. Resolution should be appropriate to the reason for testing.c.Karyotype: 2 cells. If more than 1 clone (as defined in Section E3.1.1) isfound, karyotype 1 cell representative of each clone identified.E4.1.3.2In Situ Techniquea.Count: a minimum of 15 cells from at least 15 colonies (15 cells from atleast 10 colonies if 15 colonies are not available), distributed as equallyas possible between at least 2 independently established cultures. Documentany numerical/structural aberrations observed.b.Analyze: 5 cells, each from a different colony, preferably from at least 2independently established cultures. Resolution should be appropriate to thereason for testing.c.Karyotype: 2 cells. If more than 1 clone (as defined in Section E3.1.1) isfound, karyotype 1 cell representative of each clone.E4.1.4Chorionic Villus Sample (CVS): Processing StandardsE4.1.4.1When direct (uncultured) preparations are used clinically, a cell culture technique (defined as longer than 48 hours) must also be used.E4.1.4.2Final written reports should include a summary of the results of the cultured cells.E4.1.4.3 A laboratory planning to establish CVS cytogenetics should already be testing amniotic fluid cells by established standards and methods. Prior to independentCVS analysis, the laboratory must:a.split and confirm at least 25 consecutive samples with a laboratory alreadyperforming CVS cytogenetics by established standards and methods, orb.perform CVS cytogenetics on 50 consecutive samples not used for diagnosticpurposes and confirm that the karyotype of the abortus was identical to thatof the CVS study, orc. a combination of a) and b) above.E4.1.5Chorionic Villi: Analytical Standards (see also E3.1.6)E4.1.5.1Direct (Uncultured) Preparations: not recommended for exclusive use in obtaining final results. (See Section E4.1.5.3 below.)E4.1.5.2Cultured Preparations, (Flask or Coverslip) Techniquea.Count: a minimum of 20 cells distributed as equally as possible between atleast 2 independently established cultures. Document anynumerical/structural aberrations observed.b.Analyze: 5 cells, preferably from 2 independently established cultures.Resolution should be appropriate to the reason for testing.c.Karyotype: 2 cells. If more than 1 clone (as defined in section E3.1.1) isfound, karyotype 1 cell representative of each clone.E4.1.5.3Combination of Direct Preparation and Culture Techniquea.Count: a minimum of 20 cells, at least 10 of which come from culturedpreparations. Document any numerical/structural aberrations observed.b.Analyze: 5 cells, preferably at least 4 cells from cultured preparations.Resolution should be appropriate to the reason for testing.c.Karyotype: 2 cells. If more than 1 clone (as defined in Section E3.1.1) isfound, karyotype 1 cell representative of each clone.E4.2Fetal Blood: Percutaneous Blood Sampling (PUBS)E4.2.1Processing StandardsE4.2.1.1Results of assays confirming the fetal origin of such specimens should be available to the laboratory.E4.2.1.2 A minimum of 2 cultures should be established.E4.2.1.3Processing after 48 and 72 hours in culture is recommended.E4.2.1.4Final reports (verbal or written) should be available within 7 calendar days.E4.2.2Analytical Standards (see also E3.1.6)a.Count: a minimum of 20 cells.b.Analyze: 5 cells. Resolution should be appropriate to the reason fortesting.c.Karyotype: 2 cells. If more than 1 clone (as defined in section E3.1.1) isfound, karyotype 1 cell representative of each clone.E5Peripheral Blood and Solid Tissue Constitutional Chromosome StudyE5.1Peripheral Blood (Stimulated Lymphocytes): Routine StudiesE5.1.1Processing StandardsE5.1.1.1At least 2 cultures should be established for each specimen.E5.1.1.2At least 90% of all routine peripheral blood analyses must have final written reports completed within 28 calendar days (21 calendar days is recommended) fromreceipt of the specimen. Clinical indications may dictate more rapid turn-aroundtime. Specialized stains and studies may take longer.E5.1.1.3Test failures should not exceed 2% per year.E5.1.1.4The 550-band stage should be the goal of all constitutional studies to rule out a structural abnormality, particularly in cases of mental retardation, birthdefects, dysmorphology, or couples with recurrent pregnancy loss.E5.1.2Analytical Standards (see also E3.1.6)E5.1.2.1 a.Count: a minimum of 20 cells, documenting any numerical/structuralabnormalities observed.b.Analyze: 5 cells. Resolution should be appropriate to the reason fortesting.c.Karyotype: 2 cells. If more than 1 clone (as defined in Section E3.1.1) isfound, karyotype 1 cell representative of each clone.E5.1.2.2Cases being studied for possible sex chromosome abnormalities, in which mosaicism is common, should include a minimum of 30 cells counted.E5.2Peripheral Blood (Stimulated Lymphocytes): Focused HighResolution AnalysisE5.2.1Analytical StandardsE5.2.1.1Focused high resolution analysis should be reserved for cases in which a specific microabnormality syndrome is being considered, the diagnosis of which generallyrequires chromosomes above the 650-band stage (resolution at the 850 level isrecommended). In addition, it can be applied to cases requiring the improvedcharacterization of an identified chromosome abnormality. In many situations, insitu hybridization may be a supplemental approach to specific microdeletionanalysis.E5.2.1.2General processing and analytical standards for routine peripheral blood studies apply. In addition, in a focused analysis, the primary analytical standard mustbe that the specific chromosomal region in question is visible and clearlyseparated from adjoining bands in both homologues, or in abnormal cases, in thenormal homolog.E5.3Peripheral Blood (Stimulated Lymphocytes): Complete High Resolution AnalysisE5.3.1Analytical StandardsE5.3.1.1General processing and analytical standards for routine peripheral blood studies apply. In addition, complete high resolution chromosome analysis should alwaysinclude a minimum of 3 pairs of each chromosome at a level of resolution abovethe 650-band stage (resolution at the 850 level is recommended).E5.4Peripheral Blood (Stimulated Lymphocytes): Heritable Fragile Sites (Including Fragile X)This section initially provided guidelines for the evaluation of patients forfragile X syndrome using the cytogenetic expression of the Xq27.3 (FRAXA) fragilesite. Such chromosome testing has been largely replaced by molecular genetic DNAevaluation of the FMR1 locus, and specific College recommendations have beenpublished to cover such testing (see Section FX, "Technical Standards andGuidelines for Fragile X"). However, because some laboratories may still includefragile site screening in the chromosome study portion of fragile X testing, andcytogenetic testing for other heritable fragile sites is requested under someclinical circumstances, the following guidelines are recommended.E5.4.1Processing StandardsE5.4.1.1Fragile site expression should be assessed using at least two different culture induction systems; i.e., low folate and an anti-metabolite for folate-sensitivefragile sites, BrdU and distamycin A for BrdU-inducible sites.E5.4.2Analytical StandardsE5.4.2.1Scoring for a fragile site is analogous to the exclusion of chromosomal mosaicism, and at least 59 cells total from the two cultures should be scored.E5.4.2.2In reporting of results, fragile site nomenclature must follow ISCN 1995, and it is recommended that the report contain both the methods of induction andfrequency of fragile site expression.E5.4.2.3Where possible, for clinically significant fragile sites, i.e., FRAXA, all fragile site positive individuals should be confirmed with molecular genetictesting. (Fragile site expression must not be used for fragile X syndrome [FRAXA]premutation carrier evaluation.)E5.5Solid Tissues (Skin, Organs, Products of Conception, etc.)E5.5.1Processing StandardsE5.5.1.1Tissue biopsy specimens and small specimens should be transported in sterile cell culture medium with or without serum. Sterile saline solution may be used ifmedium is not available. Larger specimens should be transported according towritten guidelines in each laboratory.E5.5.1.2At least two independent cultures should be established (three are recommended for resolving questions of mosaicism). These can be from explants of tissue grownin flasks or from enzyme-dissociated cells that can be processed in flasks or insitu.E5.5.2Analytical StandardsSee amniotic fluid guidelines (E4.1.3) for analytical standards.E5.5.2.1When sex chromosome anomalies are suspected, at least 30 cells should be counted and scored for sex chromosome complement.E5.5.3Except for products of conception (POC), test failure rates should not exceed 5% per year, in total. It is suggested that periodic monitoring of POCs be done toassure that the ratio of 46,XX: 46,XY results approximates 1:1.E5.6Bone marrow studies for constitutional disorders for detection of a lethal abnormality (e.g., trisomy 13) in a newborn may be performed. However, thesestudies have largely been replaced by direct preparation or short term culturesof peripheral blood or interphase FISH analysis. When bone marrow studies areundertaken, these studies should include a routine peripheral blood evaluationunless bone marrow study achieves the 400-band level or a resolution levelappropriate to the clinical indication for testing.E5.7Chromosome Instability Syndromes: Peripheral Blood Breakage AnalysesE5.7.1General StandardsThe rarity of chromosome instability syndromes requires that inexperiencedlaboratories should refer cases to reference laboratories with experience indiagnosing such disorders. Additionally, as research leads to the identificationand cloning of the putative disease genes, molecular testing is recommended tosupplement cytogenetic analysis.E5.7.1.1G-banded or unbanded preparations may be applied, depending upon the particular goal of the study. Unbanded preparations are acceptable only if there is no needto identify abnormalities such as translocations or inversions that will not bevisible in unbanded preparations.All abnormalities should be recorded using appropriate ISCN 1995 designations.E5.7.2Fanconi AnemiaCytogenetic evaluation for Fanconi anemia (FA) should include analysis ofcrosslinking agent (e.g., mitomycin C [MMC], diepoxybutane [DEB]) induction ofbreakage in addition to baseline chromosome breakage.E5.7.2.1Culture ConditionsEach laboratory should have well-established negative control (non-Fanconi) andpositive control (Fanconi) ranges for each culture (with and without mutagen)condition. Each new lot number of crosslinking agent should be appropriatelyquality controlled for its efficacy and potency for inducing chromosomalbreakage. Given variability between drug lots, and the need to routinely preparefresh stock and working solutions for most of the crosslinking agents, paralleltesting of control specimens is recommended, as necessary. When a sufficientamount of blood specimen (and cell count) is available, two drug-treated cultures(e.g., either two different concentrations of either DEB or MMC, or one cultureeach of MMC and DEB) are recommended.E5.7.2.2Chromosome Breakage AnalysisOptimally, 50 metaphase cells (banded or unbanded) should be scored from eachculture condition. The average rate of chromosomal aberrations per cell or thedistribution of aberrations among cells should be compared to negative andpositive control reference ranges. The percentage of cells demonstratingaberrations should be reported to enable identification of those patients who aremosaic for mutant and wild type cells.E5.7.3Bloom SyndromeCytogenetic evaluation for Bloom syndrome must include assessment of baselinesister chromatid exchange (SCE) rates.As the Bloom syndrome gene BLM has been cloned, molecular evaluation to identifythe mutation may be possible to supplement a positive cytogenetic result.E5.7.3.1Culture ConditionsEach laboratory should have well-established negative (non-Bloom syndrome) andpositive (Bloom syndrome) control SCE ranges. Duplicate cultures should beestablished both from the patient and a concurrently processed negative control.Cultures should be supplemented with bromodeoxyuridine and maintained in darknessprior to harvesting. Cells should be cultured for the period of timepredetermined by the laboratory to yield a high percentage of cells in seconddivision. At the discretion of the laboratory director, cultures for evaluationof baseline chromosome breakage may also be established.E5.7.3.2AnalysisFor confirmation of a negative result, fifty metaphase cells (25 from each of thetwo duplicate cultures) should be evaluated. For a positive result, fewer cellsmay be evaluated. However, it is recommended that both cultures from the patientand at least one from the concurrent control be sampled in the evaluation.E5.7.4Ataxia Telangiectasia and Nijmegen Breakage SyndromeCytogenetic evaluation for ataxia telangiectasia (A-T) and Nijmegen breakagesyndrome (NBS) should include specific screening for rearrangements involvingchromosomes 7 and/or 14.Evaluation for A-T and NBS should include evaluation of sensitivity to radiation.Although such sensitivity can be assessed by cytogenetic methods, it generally isevaluated by survival assays on lymphoblastoid or fibroblast cells.As the (A-T) gene (ATM) and the NBS gene (NBS1) have been cloned, molecularevaluation may be helpful for confirming the diagnosis in patients who havepositive cytogenetic and/or radiosensitivity assays.E5.7.4.1Culture ConditionsEach laboratory should have well-established negative (non-A-T, non-NBS) andpositive (A-T or NBS) control chromosome 7/14 rearrangement and chromosomebreakage rates. Duplicate stimulated cultures should be established for eachpatient case, and cultured for 48-96 hours identical to the conditions utilizedfor the establishment of the laboratory's control ranges.E5.7.4.2AnalysisAnalysis should include 50 G-banded metaphase cells screened for rearrangementsinvolving chromosomes 7 and/or 14. Overall breakage and rearrangement rates mayalso be helpful. It should be noted that, among confirmed A-T patients, thefrequency of 7/14 rearrangements increases with age. Thus, negative resultsshould be interpreted with caution. Among healthy controls, rearrangements ofchromosomes 7 and 14 are well documented in PHA-stimulated cultures. Thus,comparison to laboratory norms for age-matched controls is essential.E5.7.5MiscellaneousCytogenetic evaluation of chromosome breakage may also be undertaken for otherreasons, e.g., prior exposure to clastogens. The specific culture methodsutilized (e.g., timing of cultures) and the methods of analysis (G-banded vs.unbanded chromosomes) should be appropriate to the referral. The laboratoryshould have well established positive and negative control ranges for thespecific analyses being conducted.E6Chromosome Studies for Acquired AbnormalitiesMost cytogenetic analyses to detect and characterize acquired chromosomal。
日本药典 人参
GinsengGinseng RadixニンジンGinseng is the root of Panax ginseng C. A. Meyer(Panax schinseng Nees) (Araliaceae), from which rootlets have been removed, or the root that has been quickly passed through hot water.It contains not less than 0.10z of ginsenoside Rg1 (C42H72O14: 801.01) and not less than 0.20z of ginsenoside Rb1 (C54H92O23: 1109.29), calculated on the basis of dried material. Description Thin and long cylindrical to fusiform root, often branching 2 to 5 lateral roots from the middle; 5 – 20 cm in length, main root 0.5 – 3 cm in diameter; externally light yellow-brown to light grayish brown, with longitudinal wrinkles and scars of rootlets; sometimes crown somewhat constricted and with short remains of rhizome; fractured surface practically flat, light yellow-brown in color, and brown in the neighborhood of the cambium.Odor, characteristic; taste, at first slightly sweet, followed by a slight bitterness.Identification(1) On a section of Ginseng add dilute iodine TS dropwise: a dark blue color is produced on the surface.(2) To 2.0 g of pulverized Ginseng add 20 mL of methanol, boil gently under a reflux condenser on a water bath for 15 minutes, cool, filter, and use the filtrate as the sample solution. Separately, dissolve 1 mg of Ginsenoside Rg1 Reference Standand in 1 mL of methanol, and use this solution as the standard solution. Perform the test with these solutions as directed under Thin-layer Chromatography <2.03>. Spot 10 mL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with the lower layer of a mixture of chloroform, methanol and water (13:7:2) to a distance of about 10 cm, and air-dry the plate. Spray evenly dilute sulfuric acid on the plate, and heat at 110℃for 5 minutes: one of the spots from the sample solution and a red-purple spot from the standard solution show the same color tone and the same Rf value.Purity(1) Foreign matter <5.01>-The amount of stems and other foreign matter contained in Ginseng does not exceed 2.0%.(2) Heavy metals <1.07>—Proceed with 1.0 g of pulverized Ginseng according to Method 4, and perform the test. Prepare the control solution with 1.5 mL of Standard Lead Solution (not more than 15 ppm).(3) Arsenic <1.11>—Prepare the test solution with 1.0 g of pulverized Ginseng according to Method 4, and perform the test (not more than 2 ppm).(4) Total BHC's and total DDT's <5.01>—Not more than 0.2 ppm, respectively.Loss on drying <5.01> Not more than 14.0% (6 hours).Total ash <5.01> Not more than 4.2%.Extract content <5.01> Dilute ethanol-soluble extract: not less than 14.0%.Assay(1) Ginsenoside Rg1—Weigh accurately about 1.0 g of pulverized Ginseng, put in a glass-stoppered centrifuge tube, add 30 mL of diluted methanol (3 in 5), shake for 15 minutes, centrifuge, and separate the supernatant liquid.Repeat the procedure with the residue using 15 mL of diluted methanol (3 in 5), combine the supernatant liquids, and add diluted methanol (3 in 5) to make exactly 50mL. Pipet 10mL of this solution, add 3 mL of dilute sodium hydroxide TS, allow to stand for 30 minutes, add 3 mL of 0.1 mol/L hydrochloric acid TS and diluted methanol (3 in 5) to make exactly 20 mL, and use this solution as the sample solution. Separately, weigh accurately about 10 mg of Ginsenoside Rg1Reference Standard (previously determine the water) dissolve in diluted methanol (3 in 5) to make exactly 100mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, AT and AS, of ginsenoside Rg1.Amount (mg) of ginsenoside Rg1 (C42H72O14)=WS×(AT/AS)WS: Amount (mg) of Ginsenoside Rg1 Reference Standard, calculated on the anhydrous basis Operating conditions—Detector: An ultraviolet absorption photometer (wavelength: 203 nm).Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 μm in particle diameter).Column temperature: A constant temperature of about 30℃.Mobile phase: A mixture of water and acetonitrile (4:1).Flow rate: Adjust the flow rate so that the retention time of ginsenoside Rg1 is about 25 minutes. System suitability—System performance: Dissolve 1 mg each of Ginsenoside Rg1 Reference Standard and ginsenoside Re in diluted methanol (3 in 5) to make 10 mL. When the procedure is run with 10 μL of this solution under the above operating conditions, ginsenoside Rg1 and ginsenoside Re are eluted in this order with the resolution between these peaks being not less than 1.5.System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of ginsenoside Rg1 is not more than 1.5%.(2) Ginsenoside Rb1—Use the sample solution obtained in (1) as the sample solution. Separately, weigh accurately about 10 mg of Ginsenoside Rb1 Reference Standard (previously determine the water) dissolve in diluted methanol (3 in 5) to make exactly 100 mL, and use this solution as the standard solution. Perform the test with exactly 10 μL each of the sample solution and standard solution as directed under Liquid Chromatography <2.01> according to the following conditions, and determine the peak areas, AT and AS, of ginsenoside Rb1.Amount (mg) of ginsenoside Rb1 (C54H92O23)=WS×(AT/AS)WS: Amount (mg) of Ginsenoside Rb1 Reference Standard, calculated on the anhydrous basis Operating conditions—Detector: An ultraviolet absorption photometer (wavelength: 203 nm).Column: A stainless steel column 4.6 mm in inside diameter and 15 cm in length, packed with octadecylsilanized silica gel for liquid chromatography (5 mm in particle diameter).Column temperature: A constant temperature of about 40℃.Mobile phase: A mixture of water and acetonitrile (7:3).Flow rate: Adjust the flow rate so that the retention time of ginsenoside Rb1 is about 20 minutes. System suitability—System performance: Dissolve 1 mg each of Ginsenoside Rb1 Reference Standard and ginsenoside Rc in diluted methanol (3 in 5) to make 10 mL. When the procedure is run with 10 μL of this solution under the above operating conditions, ginsenoside Rb1 and ginsenoside Rc are eluted in this order with the resolution between these peaks being not less than 3.System repeatability: When the test is repeated 6 times with 10 μL of the standard solution under the above operating conditions, the relative standard deviation of the peak area of ginsenoside Rb1is not more than 1.5%.。
帝斯曼公司与罗盖特公司共同建设生物琥珀酸中试装置
帝斯曼公司与罗盖特公司共同建设生物琥珀酸中试装置小仓红叶
【期刊名称】《生物产业技术》
【年(卷),期】2008(000)005
【摘要】@@ 2008年1月,荷兰帝斯曼(DSM)公司和法国罗盖特(Roquette)公司宣布共同开发发酵法可再生琥珀酸生产技术并实现商业化生产.
【总页数】1页(P5)
【作者】小仓红叶
【作者单位】无
【正文语种】中文
【相关文献】
1.帝斯曼与罗盖特生产生物琥珀酸的合资企业Reverdia投入运营 [J],
2.帝斯曼和罗盖特将于2012年建成商业化规模的生物基琥珀酸工厂 [J],
3.帝斯曼公司将于2012年生产生物基琥珀酸 [J], 章文
4.帝斯曼公司将己二酸纳入其生物基化学品业务清单中 [J],
5.帝斯曼和法国罗盖特公司计划新建1套商业规模生物基琥珀酸装置 [J], 庞晓华因版权原因,仅展示原文概要,查看原文内容请购买。
PFERD研磨工具使用说明书
11/2018 以技术性修改为准。
August Rüggeberg GmbH & Co. KG · PFERD-Werkzeuge Hauptstrasse 13 · D-51709 Marienheide · PFERD产品质量符合ISO 9001认证。
本用户信息依照欧盟2001/95/ EC 有关一般产品安全性指令。
”和“有关产品投放市场的法规”总结了PFERD品牌的粗磨磨片、切割片、杯形砂轮、磨碟、金刚石切割磨片、POLIFAN百叶盘,CC-GRIND系列磨片和CC-GRIND-SOLID系列磨片(以下简称为研磨工具)在手持式磨机,手持式切割机和固定式切割机上(两者在下文中均简称为磨机)安全使用的必要信息。
在遵守该用户信息的同时,还必须遵守所用磨床的用户信息以及有关劳动安全与健康防护的规定。
有关研磨工具标记的说明■■务必注意研磨工具、磨机以及随附用户信息中的指示。
■■PFERD磨料符合欧洲最严格的质量和安全要求。
这些产品标有相应的EN标准编号,及“oSa”标记: •EN 12413粘合磨料磨具的安全要求(粗磨磨片,切割片,杯形砂轮,砂轮) •EN 13236金刚石或氮化硼磨具的安全要求 (金刚石切割磨片)•EN 13743涂附磨具产品的安全要求 (POLIFAN百叶盘,CC-GRIND系列磨片)■■请使用适用于相应应用的研磨工具。
标识不完整的工具不能使用。
■■请注意研磨工具、随附标签或包装上对用途的限制以及警告或安全指示:不得用于徒手和手工打磨不得用于侧磨不得用于湿磨如果损坏,请勿使用使用时加装背盘用遵守安全建议使用护眼装置使用护耳装置使用手套使用防尘口罩■■研磨工具及粘合类型B(例如杯形磨片)和BF(粗磨磨片,切割磨片,砂轮)在到期日之后,不得用于徒手研磨。
到期日期标记为月份和年份,例如:04/2017。
粘合类型必须始终在标签上注明。
研磨工具的存放■■研磨工具必须妥善存放,避免遭受湿气、冰霜和温度剧烈波动及机械损伤等不利影响。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
Complexity
The complexity work with Hartmanis appeared in b”th a c”nfcrmcc vrrsi”” [5] and a,jownal version [6].’ ‘I’he cow ference versi”n was given at the Fifth Annual Symposium “n Switching Circuit Theory and Logical Design which has underg”ne a couple of name changes and is now known as FOGS (Foundations of Computer Science). B”th versions of the article had the phrase “computational complexity” in their title, the tint time this phrase was used. Thus, we were the first t” call what we were doing “computational comptrxity.” Although the conference version appeal-cd brforr the ,j”urnat vetsion, the text of the conference version was written later and referred to i&elf as an “update” “n the ,j”omat version. One updatr was inclusion “f a reference t” Blum’s Ph.D. thesis from MIT which was t” apprar as [I]. This work, developed independently of ours, provided a more abstract view of complexity classes. ‘Ibis was a very significant contribution wbicb should also be credited with inspiring the rarly intet-est and rapid growth of the complexity field. In [ti], we developed our theory on input-lrrs multitape Turing machines which produced an infinite sequence of zeros and ones. This ws essentially the same model used by Yamada in his wark about ‘irrat-time countable functions” (141. How~ever, the now famitiw language recognition model was rapidly ascending t” the prominent positi”” in aut”mata thtuxy it holds today. Recognizers are a valuable model because, despite their simplistic yes/no outputs, they are aheady sufficient t” discuss mat computational issues. Furthermore, they ax ideally suited for the study of nondeterminism. In the update, we discussed the application of our methods to this model. A third update was to discuss the implication of using the Hennir-Stearns two-tape n lrrg n simulation [7] instead “f the Hartmanis-Stearns one-tape ny simulation. (Fred Hennie worked at GE from time t” time as a visitor.) The implication was a sharper, s&i&m condition for distinguishing complexity classes. The primary contribution “f OUT work was the USF of deterministic time to define complexity classes. Using modern tmtati”” and the language recognition model, our definition was this:ຫໍສະໝຸດ AwardTurCng
It’s Time to
-
Richard Edwin Stearns
lo 1960, I was hired by Richatd 1.. Sbuey t” wnrk fix the xtmmer at Genes-al Electric’s Rrsrarcb Laboratory in Schenectady, NCK Y”rk. Shuey was manager of a group called the “Inf”mlatiott Studies Section” which included ,Juria Hartmania and Philip M. Lewis II. This g-mop was part “f a larger gr”up ratted “Electron Physics.” During that summer, 1 worked with Hartmanib continuing s”me work hr had started “n the decomposition of sequential machines. As a result, the first Harrmanis-Stearns article [Y] was pt-aducect. 1 was very impressed with the quality “f the people at GE and the freedom thry had to define their own research goats. ‘l‘hus, when Shuey invited me f” rcturn in l9til as a permanent employee, I ,jumped at thr chance. There were a nombcr of jokes made ab”ut my Ph.D. thesis since GE had just settled an antitrust suit for cooperating with tw” “thcr companies t” fix prices (no ride payments involved!). When l started at GE, it was strictly as a mathematician. The resrarch laboratory did not have a computer and 1 had never used i, computer. A few yews later, the taboratory “brained a GE300 and installed a copy of the timrsharing system developed at Dartmouth. My first programming experiences we,-e using Basic on this machine thr”ugh a teletype interface. These cxprricnces came slier Hartmanis and I had worked “ut our thrwy “fconlputarionat camplexity. My eansformation intr) a c”mputer scientist was a matter “f evolution rather than a conscious decision. I was pursuing the mathematical problems I f”und mwt interesting and fbund myself in the middle of computer science. l continue t” hold a simultanr”us interest in both game theory and computer science. In fact, my lint article with Hartmanis preceded my thesis wwk. You may wonder if these fields have anything in common. I think they d”. One commonality is that they were both started by John v”n Neumann. The beginning “f game theory is clearly marked by the famous hook by van Neumann and Morgemtern [l3] and van Neumann with his “wm Neumann stored pr”gram computer model” is also considered a frmnding father of computer science. A second thing they have in c”mm”n is the need t” understand something very intangible yet very real. In the case “fgame theory, it is the nature ofcompetition. In the case of computer science, it is the nature of computathm. Both areas have required s”me completely new mathematics Irequiring the development of new mathematical models. My attracti”n COgame thewy began as an undergraduate one summer when I l.eead [IS] for recrration and saw how much attend”” was given to discus&n about the choices of model. To me, the mat interesting mathematics is that which tells us something about the real world. Thus, the first question we as mathematicians and computer scientists should ask is “how well do our models reflect the salient features of the objects or situations we wish to describe?” The significance “fa result depends m”re on the information it conveys rather than on the complexity of its proof. Ga,hage-in/garbage-out applies t” theory as well as software.